Schering's Specialty Focus Includes Alzheimer's, Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough's specialty drug pipeline - part of big pharma's overall efforts to hedge against the dwindling primary care market - includes several potential first-in-class or best-in-class compounds addressing oncology, Alzheimer's disease, Parkinson's disease and other specialty areas
You may also be interested in...
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
BMS Outlines Clinical Trial Disruptions, Reassures Supply Chain Secure
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: